Evidence map›Paper›PMID 39963340›Full record

ArticleJBMR plus2025

Excess fibroblast growth factor 23 in alcoholic osteomalacia is derived from the bone.

Naoko Hidaka, Yuko Oyama, Minae Koga, Naoki Kondo, Yoichi Yasunaga, Taketoshi Shimakura, Noriaki Yamamoto, Hideaki E Takahashi, Yoichi Iwafuchi, So Watanabe and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JBMR plus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Naoko HidakaDivision of Nephrology and Endocrinology, The University of Tokyo Hospital, Tokyo 113-8655, Japan.ORCID https://orcid.org/0000-0002-5450-2247
Yuko OyamaDepartment of Nephrology, Saiseikai Niigata Kenoh Kikan Hospital, Niigata 955-0091, Japan.
Minae KogaDivision of Nephrology and Endocrinology, The University of Tokyo Hospital, Tokyo 113-8655, Japan.
Naoki KondoDivision of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan.
Yoichi YasunagaDepartment of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Taketoshi ShimakuraNiigata Bone Science Institute, Niigata 950-3304, Japan.
Noriaki YamamotoNiigata Bone Science Institute, Niigata 950-3304, Japan.
Hideaki E TakahashiNiigata Bone Science Institute, Niigata 950-3304, Japan.
Yoichi IwafuchiDepartment of Nephrology, Saiseikai Niigata Kenoh Kikan Hospital, Niigata 955-0091, Japan.
So WatanabeOsteoporosis Center, The University of Tokyo Hospital, Tokyo 113-8655, Japan.
Soichiro KimuraDivision of Nephrology and Endocrinology, The University of Tokyo Hospital, Tokyo 113-8655, Japan.
Yoshitomo HoshinoDivision of Nephrology and Endocrinology, The University of Tokyo Hospital, Tokyo 113-8655, Japan.
Hajime KatoDivision of Nephrology and Endocrinology, The University of Tokyo Hospital, Tokyo 113-8655, Japan.ORCID https://orcid.org/0000-0001-9178-7846
Yuka KinoshitaDivision of Nephrology and Endocrinology, The University of Tokyo Hospital, Tokyo 113-8655, Japan.
Hiroshi KobayashiOsteoporosis Center, The University of Tokyo Hospital, Tokyo 113-8655, Japan.
Takeyuki TanakaOrthopedic Surgery, Sensory and Motor System Medicine, Surgical Sciences, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Tetsuo UshikuDepartment of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Masaomi NangakuDivision of Nephrology and Endocrinology, The University of Tokyo Hospital, Tokyo 113-8655, Japan.
Sakae TanakaDepartment of Orthopedic Surgery, The University of Tokyo Hospital, Tokyo 113-8655, Japan.ORCID https://orcid.org/0000-0001-9210-9414
Noriko MakitaDivision of Nephrology and Endocrinology, The University of Tokyo Hospital, Tokyo 113-8655, Japan.
Taku SaitoOsteoporosis Center, The University of Tokyo Hospital, Tokyo 113-8655, Japan.
Nobuaki ItoOsteoporosis Center, The University of Tokyo Hospital, Tokyo 113-8655, Japan.ORCID https://orcid.org/0000-0002-4071-5372

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Excess fibroblast growth factor 23 (FGF23), a mature osteocyte-derived phosphaturic hormone, causes chronic hypophosphatemic osteomalacia in adults. This rare condition was recently reported in 2 alcoholic patients, with marked improvement upon cessation of alcohol consumption, suggesting a link between alcohol and FGF23-related hypophosphatemia within the highly limited cases. This study aimed to investigate whether the source of excess FGF23 in alcohol-induced FGF23-related hypophosphatemic osteomalacia is the bone or the other organs. To achieve this goal, an immunohistochemical approach for the bone obtained from a patient was employed. Initial attempts at quantifying FGF23 in the bone using conventional immunohistochemistry (IHC) faced issues in quantifiability and sensitivity for low FGF23 expression levels. Therefore, next-generation IHC with phosphor-integrated dots (PIDs) was applied, which enabled the quantification of FGF23 expression in the bone across a broad range. Preliminary analyses using IHC with PIDs on normal bone samples (

Indexed as

alcoholdifferential diagnosisfibroblast growth factor 23hypophosphatemiaimmunohistochemistryosteomalacia

Identifiers

PMID39963340
PMCPMC11831984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.